Credit CDC PHIL
# 9531
Last month we saw a temporary halt to testing of Merck’s Ebola vaccine (see Ebola Vaccine Trial Halted Temporarily After Joint Pains: Geneva Hospital), when four of the first fifty-nine recipients reported minor side effects. Meanwhile, clinical trials on the GSK vaccine candidate (see NIH Statement On Early Ebola Vaccine Trial Data) were described as being `well-tolerated and produced immune system responses in all 20 healthy adults who received it.’
The adverse symptoms reported in the Merck trial were apparently minor, and resolved without treatment over a matter of a few days, and so the decision has been made to continue to the testing at Geneva’s University Hospital, albeit with markedly lower doses of vaccine particles.
This report from Reuters:
Merck-NewLink Ebola vaccine trial resumes at lower dose -Geneva hospital
GENEVA Mon Jan 5, 2015 7:53am EST
Jan 5 (Reuters) - The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers, the University of Geneva hospital said.
